Outpatient Treatment of Haemophilus influenzae Pneumonia in Healthy Adults Without Comorbidities
Clinical Scenario
This protocol covers an adult presenting in the outpatient setting with community-acquired pneumonia who has no significant chronic comorbidities and no identifiable risk factors for antibiotic-resistant pathogens.
Patient Profile
All of the following must apply:
- No chronic heart, lung, liver, or renal disease
- No diabetes mellitus, alcoholism, malignancy, or asplenia
- No prior respiratory isolation of MRSA or P. aeruginosa
- No recent hospitalisation with receipt of parenteral antibiotics in the last 90 days
Treatment Approach (partial overview)
In this low-risk outpatient population, oral antibiotic monotherapy is the recommended strategy, with agent selection informed by local resistance patterns. Treatment is continued until clinical stability is reached and for no fewer than 5 days total.
The full regimen — including specific antibiotic options and the complete selection algorithm — is available in the structured protocol below.
Clinical Target
The treatment goal is clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Most patients reach stability within 48 to 72 hours.
References
DOI: 10.1164/rccm.201908-1581ST
- For healthy outpatient adults without comorbidities listed below or risk factors for antibiotic resistant pathogens, we recommend (Table 3):
- Comorbidities include chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia.
- Risk factors include prior respiratory isolation of MRSA or P. aeruginosa or recent hospitalization AND receipt of parenteral antibiotics (in the last 90 d).
- amoxicillin 1 g three times daily (strong recommendation, moderate quality of evidence), or
- doxycycline 100 mg twice daily (conditional recommendation, low quality of evidence), or
- a macrolide (azithromycin 500 mg on first day then 250 mg daily or clarithromycin 500 mg twice daily) only in areas with pneumococcal resistance to macrolides <25% (conditional recommendation, moderate quality of evidence).
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗